CytomX Therapeutics, Inc. is committed to changing the treatment of cancer with our novel PROBODY® therapeutic platform. Our commitment to transforming lives with safer, more effective therapies is driven by our curiosity and passion for innovation and our belief that by acting with integrity in an honest, respectful, ethical manner, we have the power to change lives. Our workplace embodies collaboration, open communication, celebrating our successes, and holding each other to the highest possible standards. CytomX’s robust and differentiated pipeline comprises therapeutic candidates across multiple treatment modalities including antibody-drug conjugates (“ADCs”), T-cell engagers, and immune modulators such as cytokines. CytomX’s clinical-stage pipeline includes CX-2051 and CX-801. Learn more at www.cytomX.com . You are passionate about life sciences and making a difference to cancer patients, their families, and healthcare providers. You will be responsible for Developing robust research scale conjugation process to support multiple PROBODY Drug Conjugate (PDC) discovery programs. Developing novel conjugation strategies/technologies to generate cutting-edge PDCs for the treatment of various cancers. Developing strategies for the chemical synthesis of novel linker payloads for PDCs Working closely with the CMC team to transition the PDCs into clinical development
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Career Level
Mid Level
Education Level
Ph.D. or professional degree
Number of Employees
11-50 employees